



CLS expands the management team – appoints Executive Vice President Operations

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) announces today that the company has appointed Jimmy Johansson as Executive VP Operations. Jimmy has worked within CLS since 2015 in various roles focused on management within research and development.

The appointment of an Executive Vice President Operations, which is a newly created role in the company, is part of CLS's continued growth strategy and will constitute an important function in the company's commercial expansion and in securing the company's offering to the market. In the role of Executive VP Operations, Jimmy will be part of the company's executive management team.

“This is a new coordinating management function created to streamline our operation and secure the company's continued growth. Jimmy already has good insight into and understanding of CLS's business, he possesses a broad competence and good leadership skills. Jimmy will be an important resource for us as the company grows commercially”, says Dan Mogren, CEO Clinical Laserthermia Systems AB.

Jimmy Johansson has extensive experience from the medtech and healthcare sector, and has previously held several leading positions in business and product development, as well as quality assurance of medical devices, at various companies, including BIBBIInstruments AB, itACiH AB and Sony Mobile Communications. He has also been head of research and development at the department of biomedical technology at Skåne University Hospital, as well as worked for several years at Lund University Hospital and within Region Skåne. Jimmy has a Master's degree in electrical engineering with a specialization in biomedical engineering at Lund University.

Jimmy owns 182,105 B shares in CLS, of which 178,570 are owned via the company Medtech Öresund AB.

The information was submitted for publication, through the agency of the contact person set out below on 22 May 2023.

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: clinicallaser.se